In vitro antiviral activity of a double-stranded RNA sodium salt-based medicinal product against SARS-CoV-2

Scientific relevance. Innate immune activation in the early phases of COVID-19 infection and subsequent interferon induction may help control viral replication and protect cells not yet infected with SARS-CoV-2. Thus, immunostimulants that induce interferon (IFN), including double-stranded RNA-based agents, are a promising means of post-exposure prophylaxis and treatment of COVID-19 at early stages.

Aim. The study evaluated the in vitro antiviral activity of a double-stranded RNA sodium salt-based medicinal product against SARS-CoV-2.

Materials and methods. The authors analysed the double-stranded RNA sodium salt-based medicinal product RADAMIN^®VIRO using Vero cells and the Delta variant of SARS-CoV-2 (B.1.617). The virus titre was calculated as the tissue cytopathic dose that caused 50% cell death. The authors measured the content of IFN-α and IFN-γ in the culture fluid by enzyme immunoassay and assessed the viral load by real-time polymerase chain reaction (using the cycle threshold value) and by titration (using Vero cells).

Results. The studied double-stranded RNA sodium salt-based medicinal product at a concentration of 250 or 500 μg/mL induced IFN-α and IFN-γ expression by Vero cells, thus increasing their resistance to SARS-CoV-2. The authors evaluated the antiviral activity of the medicinal product based on the virus titre, viral load, and cell monolayer damage. The antiviral activity became clear 24 h after treatment, which confirmed the ability of the medicinal product to inhibit the replication of the SARS-CoV-2 virus in vitro as early as the first day after infection.

Conclusions. The double-stranded RNA sodium salt-based medicinal product induced IFN-α and IFN-γ synthesis in Vero cells, increasing their resistance to SARS-CoV-2 infection in vitro. These results demonstrate the immunomodulatory and antiviral potential of the medicinal product.

1. Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed. 2020;91(1):157–60. https://doi.org/10.23750/abm.v91i1.9397

2. Seyedpour S, Khodaei B, Loghman AH, Seyedpour N, Kisomi MF, Balibegloo M, et al. Targeted therapy strategies against SARS‐CoV‐2, cell entry mechanisms: A systematic review of in vitro and in vivo studies. J Cell Physiol. 2020;236(4):2364–92. https://doi.org/10.1002/jcp.30032

3. Bolevich SB, Bolevich SS. Complex mechanism of COVID-19 development. Sechenov Medical Journal. 2020;11(2):50–61 https://doi.org/10.47093/2218-7332.2020.11.2.50-61

4. Andreev-Andrievskiy AA, Zinovkin RA, Mashkin MA, Frolova OY, Kazaishvili YG, Scherbakova VS, et al. Gene expression pattern of Peyer’s patch lymphocytes exposed to kagocel suggests pattern-recognition receptors mediate its action. Front Pharmacol. 2021;12:679511. https://doi.org/10.3389/fphar.2021.679511

5. Gu W, Gan H, Ma Y, Xu L, Cheng J, Li B, et al. The molecular mechanism of SARS-CoV-2 evading host antiviral innate immunity. Virol J. 2022;19(1):49. https://doi.org/10.1186/s12985-022-01783-5

6. Kostinov MP, Markelova EV, Svitich OA, Polishchuk VB Immunological methods of SARS-CoV-2 and potential drugs for the prevention and treatment of COVID-19. Pulmonology. 2020;30(5):700–8. https://doi.org/10.18093/0869-0189-2020-30-5-700-708

7. Barnard DL, Day CW, Bailey K, Heiner M, Montgomery R, Lauridsen L, et al. Evaluation of immunomodulators, interferons and known in vitro SARS-CoV inhibitors for inhibition of SARS-CoV replication in BALB/c mice. Antivir Chem Chemother. 2006;17(5):275–84. https://doi.org/10.1177/095632020601700505

8. Day CW, Baric R, Cai SX, Frieman M, Kumaki Y, Morrey JD, et al. A new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivo. Virology. 2009;395(2):210–22. https://doi.org/10.1016/j.virol.2009.09.023

9. Overton ET, Goepfert PA, Cunningham P, Carter WA, Horvath J, Young D, Strayer DR. Intranasal seasonal influenza vaccine and a TLR-3 agonist, rintatolimod, induced cross-reactive IgA antibody formation against avian H5N1 and H7N9 influenza HA in humans. Vaccine. 2014;32(42):5490–5. https://doi.org/10.1016/j.vaccine.2014.07.078

10. Kozlowski A, Charles SA, Harris JM. Development of pegylated interferons for the treatment of chronic hepatitis C. BioDrugs. 2001;15(7):419–29. https://doi.org/10.2165/00063030-200115070-00001

11. Nicodemus CF, Berek JS. TLR3 agonists as immunotherapeutic agents. Immunotherapy. 2010;2(2):137–40. https://doi.org/10.2217/imt.10.8

12. Mustafa DAM, Saida L, Latifi D, Wismans LV, de Koning W, Zeneyedpour L. Rintatolimod induces antiviral activities in human pancreatic cancer cells: opening for an Anti-COVID-19 opportunity in cancer patients. Cancers (Basel). 2021;13(2):2896. https://doi.org/10.3390/cancers13122896

13. Ershov FI, Kiselev OI. Interferons and their inductors (from molecules to drugs). Moscow: GEOTAR-Media; 2005 (In Russ.).

14. Kozlovskaya L, Piniaeva A, Ignatyev G, Selivanov A, Shishova A, Kovpak A, et al. Isolation and phylogenetic analysis of SARS-CoV-2 variants collected in Russia during the COVID-19 outbreak. Int J Infect Dis. 2020;99:40–6. https://doi.org/10.1016/j.ijid.2020.07.024

15. Ianevski A, Yao R, Zusinaite E, Lello LS, Wang S, Jo E, et al. Synergistic interferon-alpha-based combinations for treatment of SARS-CoV-2 and other viral infections. Viruses. 2021;13(12):2489. https://doi.org/10.3390/v13122489

16. Sallard E, Lescure FX, Yazdanpanah Y, Mentre F, Peiffer-Smadja N. Type 1 interferons as a potential treatment against COVID-19. Antiviral Res. 2020;178:104791. https://doi.org/10.1016/j.antiviral.2020.104791

17. Ribero MS, Jouvenet N, Dreux M, Nisole S. Interplay between SARS-CoV-2 and the type I interferon response. PLoS Pathog. 2020;16(7):e1008737. https://doi.org/10.1371/journal.ppat.1008737

18. Todorović-Raković N, Whitfield JR. Between immunomodulation and immunotolerance: The role of IFNγ in SARS-CoV-2 disease. Cytokine. 2021;146:155637. https://doi.org/10.1016/j.cyto.2021.155637

19. Karber G. Beitragzurkollecktiven behandlungpharmakologischer reihenversuche. Arch Exptl Pathol Pharmakol. 1931;162:480–3.

20. Villinger F, Brar SS, Mayne A, Chikkala N, Ansari AA. Comparative sequence analysis of cytokine genes from human and nonhuman primates. J Immunol. 1995;155:3946–54. https://doi.org/10.4049/jimmunol.155.8.3946

21. Felger JS, Alagbe O, Hu F, Mook D, Freeman AA, Sanchez MM, et al. Effects of interferon-alpha on rhesus monkeys: a non-human primate model of cytokine-induced depression. Biol Psychiatry. 2007;62(11):1324–33. https://doi.org/10.1016%2Fj.biopsych.2007.05.026

22. Willette AA, Lubach GR, Coe CL. Environmental context differentially affects behavioral, leukocyte, cortisol, and interleukin-6 responses to low doses of endotoxin in the rhesus monkey. Brain Behav Immun. 2007;21(6):807–15. https://doi.org/10.1016/j.bbi.2007.01.007